A Glycolipid Adjuvant, 7DW8-5, Enhances CD8+ T Cell Responses Induced by an Adenovirus-Vectored Malaria Vaccine in Non-Human Primates

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Padte, Neal N ^a   Boente Carrera, Mar ^a   Andrews, Chasity D ^a   McManus, Jenny ^a   Grasperge, Brooke F ^b   Gettie, Agegnehu ^b   Coelho dos Reis, Jordana G ^a   Li, Xiangming ^a   Wu, Douglass ^c   Bruder, Joseph T ^d   Sedegah, Martha ^e   Patterson, Noelle ^e,f   Richie, Thomas L ^e   Wong, Chi Huey ^c,g   Ho, David D ^a   Vasan, Sandhya ^a,f   Tsuji, Moriya ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d GENVEC INC   (United States)

^e NAVAL MEDICAL RESEARCH CENTER   (United States)

^f HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^g ACADEMIA SINICA   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; GLYCOLIPID; MEMBRANE PROTEIN; PARASITE ANTIGEN; PHARMACEUTICAL VEHICLES AND ADDITIVES; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; INNATE IMMUNITY; MALARIA FALCIPARUM; MALE; NATURAL KILLER T CELL; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN EXPRESSION; RHESUS MONKEY; VACCINATION; ADENOVIRIDAE; ANIMAL; DRUG EFFECTS; GENE VECTOR; IMMUNOLOGY; MALARIA, FALCIPARUM; PRIMATE;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; GENETIC VECTORS; GLYCOLIPIDS; MACACA MULATTA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MEMBRANE PROTEINS; PLASMODIUM FALCIPARUM; PRIMATES; PROTOZOAN PROTEINS;

EID: 84886384042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078407     Document Type: Article

References (57)

1. Crompton PD, Pierce SK, Miller LH, (2010) Advances and challenges in malaria vaccine development. J Clin Invest 120: 4168-4178. doi:10.1172/JCI44423. PubMed: 21123952.
2. Good MF, Doolan DL, (2010) Malaria vaccine design: immunological considerations. Immunity 33: 555-566. doi:10.1016/j.immuni.2010.10.005. PubMed: 21029965.
3. Schwartz L, Brown GV, Genton B, Moorthy VS, (2012) A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 11: 11. doi:10.1186/1475-2875-11-11. PubMed: 22230255.
4. Ishii KJ, Akira S, (2007) Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 27: 363-371. doi:10.1007/s10875-007-9087-x. PubMed: 17370119.
5. Kawai T, Akira S, (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384. doi:10.1038/ni.1863. PubMed: 20404851.
6. Mitchell D, Yong M, Raju J, Willemsen N, Black M, et al. (2011) Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines. Hum Vaccin 7 (Suppl):: 85-93. doi:10.4161/hv.7.0.14567. PubMed: 21245658.
7. Warshakoon HJ, Hood JD, Kimbrell MR, Malladi S, Wu WY, et al. (2009) Potential adjuvantic properties of innate immune stimuli. Hum Vaccin 5: 381-394. PubMed: 19270494.
8. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, et al. (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8? T cell immunity. Science 334: 475-480. doi:10.1126/science.1211548. PubMed: 21903775.
9. Rodrigues MM, Cordey AS, Arreaza G, Corradin G, Romero P, et al. (1991) CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 3: 579-585. doi:10.1093/intimm/3.6.579. PubMed: 1716146.
10. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, et al. (1989) Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341: 323-326. doi:10.1038/341323a0. PubMed: 2477703.
11. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, et al. (1987) Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330: 664-666. doi:10.1038/330664a0. PubMed: 3120015.
12. Weiss WR, Jiang CG, (2012) Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLOS ONE 7: e31247. doi:10.1371/journal.pone.0031247. PubMed: 22355349.
13. Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF, (1988) CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A 85: 573-576. doi:10.1073/pnas.85.2.573. PubMed: 2963334.
14. Bassett JD, Swift SL, Bramson JL, (2011) Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors. Expert Rev Vaccines 10: 1307-1319. doi:10.1586/erv.11.88. PubMed: 21919620.
15. Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M, (1997) Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol 158: 1268-1274. PubMed: 9013969.
16. Vezys V, Yates A, Casey KA, Lanier G, Ahmed R, et al. (2009) Memory CD8 T-cell compartment grows in size with immunological experience. Nature 457: 196-199. doi:10.1038/nature07486. PubMed: 19005468.
17. Bendelac A, Rivera MN, Park SH, Roark JH, (1997) Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15: 535-562. doi:10.1146/annurev.immunol.15.1.535. PubMed: 9143699.
18. Kronenberg M, (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877-900. doi:10.1146/annurev.immunol.23.021704.115742. PubMed: 15771592.
19. Chackerian A, Alt J, Perera V, Behar SM, (2002) Activation of NKT cells protects mice from tuberculosis. Infect Immun 70: 6302-6309. doi:10.1128/IAI.70.11.6302-6309.2002. PubMed: 12379709.
20. Crowe NY, Smyth MJ, Godfrey DI, (2002) A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196: 119-127. doi:10.1084/jem.20020092. PubMed: 12093876.
21. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, et al. (2000) alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci U S A 97: 8461-8466. doi:10.1073/pnas.97.15.8461. PubMed: 10900007.
22. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, et al. (2001) The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7: 1052-1056. doi:10.1038/nm0901-1052. PubMed: 11533710.
23. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, et al. (2001) Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 194: 1789-1799. doi:10.1084/jem.194.12.1789. PubMed: 11748280.
24. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV, (2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192: 921-930. doi:10.1084/jem.192.7.921. PubMed: 11015434.
25. Kawakami K, Kinjo Y, Yara S, Koguchi Y, Uezu K, et al. (2001) Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect Immun 69: 213-220. doi:10.1128/IAI.69.1.213-220.2001. PubMed: 11119508.
26. Kawakami K, Kinjo Y, Yara S, Uezu K, Koguchi Y, et al. (2001) Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis. Infect Immun 69: 6643-6650. doi:10.1128/IAI.69.11.6643-6650.2001. PubMed: 11598033.
27. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. (1998) Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A 95: 5690-5693. doi:10.1073/pnas.95.10.5690. PubMed: 9576945.
28. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, et al. (2001) Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7: 1057-1062. doi:10.1038/nm0901-1057. PubMed: 11533711.
29. Singh AK, Wilson MT, Hong S, Olivares-Villagómez D, Du C, et al. (2001) Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 194: 1801-1811. doi:10.1084/jem.194.12.1801. PubMed: 11748281.
30. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM, (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198: 267-279. doi:10.1084/jem.20030324. PubMed: 12874260.
31. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, et al. (2002) Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195: 617-624. doi:10.1084/jem.20011889. PubMed: 11877484.
32. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, et al. (2003) NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171: 5140-5147. PubMed: 14607913.
33. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, et al. (2004) Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 114: 1800-1811. doi:10.1172/JCI22046. PubMed: 15599405.
34. Venkataswamy MM, Baena A, Goldberg MF, Bricard G, Im JS, et al. (2009) Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J Immunol 183: 1644-1656. doi:10.4049/jimmunol.0900858. PubMed: 19620317.
35. Li X, Fujio M, Imamura M, Wu D, Vasan S, et al. (2010) Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A 107: 13010-13015. doi:10.1073/pnas.1006662107. PubMed: 20616071.
36. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, et al. (1998) CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188: 1521-1528. doi:10.1084/jem.188.8.1521. PubMed: 9782129.
37. Fernandez CS, Chan AC, Kyparissoudis K, De Rose R, Godfrey DI, et al. (2009) Peripheral NKT cells in simian immunodeficiency virus-infected macaques. J Virol 83: 1617-1624. doi:10.1128/JVI.02138-08. PubMed: 19052081.
38. Gansuvd B, Goodwin J, Asiedu CK, Jiang XL, Jargal U, et al. (2008) Invariant natural killer T cells from rhesus macaque spleen and peripheral blood are phenotypically and functionally distinct populations. J Med Primatol 37: 1-11. PubMed: 18199066.
39. Motsinger A, Azimzadeh A, Stanic AK, Johnson RP, Van Kaer L, et al. (2003) Identification and simian immunodeficiency virus infection of CD1d-restricted macaque natural killer T cells. J Virol 77: 8153-8158. doi:10.1128/JVI.77.14.8153-8158.2003. PubMed: 12829854.
40. Rout N, Else JG, Yue S, Connole M, Exley MA, et al. (2010) Paucity of CD4+ natural killer T (NKT) lymphocytes in sooty mangabeys is associated with lack of NKT cell depletion after SIV infection. PLOS ONE 5: e9787. doi:10.1371/journal.pone.0009787. PubMed: 20352088.
41. Padte NN, Li X, Tsuji M, Vasan S, (2011) Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol 140: 142-151. doi:10.1016/j.clim.2010.11.009. PubMed: 21185784.
42. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, et al. (2011) Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLOS ONE 6: e24586. doi:10.1371/journal.pone.0024586. PubMed: 22003383.
43. Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, et al. (2011) Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLOS ONE 6: e25868. doi:10.1371/journal.pone.0025868. PubMed: 22003411.
44. Gardiner DF, Huang Y, Basu S, Leung L, Song Y, et al. (2006) Multiple-site DNA vaccination enhances immune responses in mice. Vaccine 24: 287-292. doi:10.1016/j.vaccine.2005.07.075. PubMed: 16137804.
45. Robinson SP, Patterson S, English N, Davies D, Knight SC, et al. (1999) Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 29: 2769-2778. doi:10.1002/(SICI)1521-4141(199909)29:09. PubMed: 10508251.
46. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, et al. (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8: 3702-3709. PubMed: 12473579.
47. Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, et al. (2007) Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol 47: 356-365. doi:10.1016/j.jhep.2007.04.018. PubMed: 17599630.
48. Woltman AM, Ter Borg MJ, Binda RS, Sprengers D, von Blomberg BM, et al. (2009) Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir Ther 14: 809-818. doi:10.3851/IMP1295. PubMed: 19812443.
49. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, et al. (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910-1917. doi:10.1158/1078-0432.CCR-04-1453. PubMed: 15756017.
50. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, et al. (2004) Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389. doi:10.1182/blood-2003-04-1155. PubMed: 14512316.
51. Schneiders FL, Scheper RJ, von Blomberg BM, Woltman AM, Janssen HL, et al. (2011) Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 140: 130-141. doi:10.1016/j.clim.2010.11.010. PubMed: 21169066.
52. Spada FM, Borriello F, Sugita M, Watts GF, Koezuka Y, et al. (2000) Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells. Eur J Immunol 30: 3468-3477. doi:10.1002/1521-4141(2000012)30:12. PubMed: 11093166.
53. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM, (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 199: 1607-1618. doi:10.1084/jem.20040317. PubMed: 15197224.
54. Parekh VV, Wilson MT, Olivares-Villagómez D, Singh AK, Wu L, et al. (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115: 2572-2583. doi:10.1172/JCI24762. PubMed: 16138194.
55. Wilson MT, Johansson C, Olivares-Villagómez D, Singh AK, Stanic AK, et al. (2003) The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci U S A 100: 10913-10918. doi:10.1073/pnas.1833166100. PubMed: 12960397.
56. Bontkes HJ, Moreno M, Hangalapura B, Lindenberg JJ, de Groot J, et al. (2010) Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide. Clin Immunol 136: 364-374. doi:10.1016/j.clim.2010.04.019. PubMed: 20570567.
57. Courtney AN, Thapa P, Singh S, Wishahy AM, Zhou D, et al. (2011) Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol 41: 3312-3322. doi:10.1002/eji.201041359. PubMed: 21818755.